GlacierGazer
Well-known member
New Nasal Vaccine Shows Early Promise in Halting Covid-19 Infection
Researchers in Germany have made a breakthrough in developing a nasal vaccine that can effectively stop the Covid-19 infection from taking hold in the nose and throat, where it first sets foot in the body. The vaccine, which is made with a live but weakened form of the coronavirus, has shown promising results in hamster studies, achieving "sterilizing immunity" and preventing illness.
The vaccine works by boosting mucosal immunity, or the immune system's defense against infections that occur in the tissues lining the upper airways. By doing so, it can prevent the virus from replicating and causing infection. The researchers believe this approach could provide a more effective solution to Covid-19 than traditional vaccines, which often rely on injecting the virus into the bloodstream.
The study's lead author, Emanuel Wyler, compared the vaccine to having firefighters stationed at the smoke alarm in your house, saying that it can quickly respond to an infection and eliminate it before it spreads. The immunity created by this vaccine is also long-lived, unlike traditional shots which only provide temporary protection.
While the results are encouraging, experts caution that more research needs to be done before the vaccine can be widely used. The researchers have partnered with a Swiss company called RocketVax to start phase I clinical trials in humans and are eagerly awaiting the results of other nasal vaccines currently in development.
One such vaccine, developed by Codagenix, uses a similar approach but has shown mixed results in studies conducted in South America and Africa. The German team is watching its progress closely and hopes that it will provide further evidence for this promising approach to Covid-19 treatment.
Despite the promise of these new nasal vaccines, experts warn that respiratory infections can be tough targets for inhaled vaccines. FluMist, a live but weakened form of the flu virus, has shown limited effectiveness in adults, highlighting the challenges of developing effective treatments for viral infections.
However, some researchers argue that live attenuated viruses can be powerful tools against certain diseases, as seen with vaccines like those against measles, mumps, and rubella. But these vaccines also pose risks for people with compromised immunity, which must be carefully weighed when considering their use.
The development of effective treatments for Covid-19 continues to be a pressing concern, and new approaches like the nasal vaccine offer hope that we may soon have more tools in our arsenal against this highly infectious disease.
Researchers in Germany have made a breakthrough in developing a nasal vaccine that can effectively stop the Covid-19 infection from taking hold in the nose and throat, where it first sets foot in the body. The vaccine, which is made with a live but weakened form of the coronavirus, has shown promising results in hamster studies, achieving "sterilizing immunity" and preventing illness.
The vaccine works by boosting mucosal immunity, or the immune system's defense against infections that occur in the tissues lining the upper airways. By doing so, it can prevent the virus from replicating and causing infection. The researchers believe this approach could provide a more effective solution to Covid-19 than traditional vaccines, which often rely on injecting the virus into the bloodstream.
The study's lead author, Emanuel Wyler, compared the vaccine to having firefighters stationed at the smoke alarm in your house, saying that it can quickly respond to an infection and eliminate it before it spreads. The immunity created by this vaccine is also long-lived, unlike traditional shots which only provide temporary protection.
While the results are encouraging, experts caution that more research needs to be done before the vaccine can be widely used. The researchers have partnered with a Swiss company called RocketVax to start phase I clinical trials in humans and are eagerly awaiting the results of other nasal vaccines currently in development.
One such vaccine, developed by Codagenix, uses a similar approach but has shown mixed results in studies conducted in South America and Africa. The German team is watching its progress closely and hopes that it will provide further evidence for this promising approach to Covid-19 treatment.
Despite the promise of these new nasal vaccines, experts warn that respiratory infections can be tough targets for inhaled vaccines. FluMist, a live but weakened form of the flu virus, has shown limited effectiveness in adults, highlighting the challenges of developing effective treatments for viral infections.
However, some researchers argue that live attenuated viruses can be powerful tools against certain diseases, as seen with vaccines like those against measles, mumps, and rubella. But these vaccines also pose risks for people with compromised immunity, which must be carefully weighed when considering their use.
The development of effective treatments for Covid-19 continues to be a pressing concern, and new approaches like the nasal vaccine offer hope that we may soon have more tools in our arsenal against this highly infectious disease.